Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphine for Dyspnea and Exercise Tolerance in Advanced COPD
NCT01718496Phase 3Unknown
- Sponsor
- McGill University Health Centre
- Start
- Jul 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Morphine Sequence with Placebo Sequence (2 arms). Primary endpoints: Improvement of Dyspnea at 1 hour and Improvement of Exercise Tolerance at 1 hour. Status: unknown.
02
Drugs
morphine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01718496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718496.